Study design and inclusion criteria
liver metastases
LIVER METASTASES
In this prospective trial sequel, we employed a parallel-group design with 1:1 randomization to the treatment and control group. All patients gave written informed consent prior to randomization.Key inclusion criteria were: (i) patients with liver metastases in non-cirrhotic liver scheduled for interstitial brachytherapy; (ii) age 18–85 years and performance status ECOG 0 or 1; (iii) no prior irradiation therapy of the liver; (iv) no restricted renal function (estimated glomerular filtration rate < 45 ml/min) and (v) no oral anticoagulants.